Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roivant Sciences Ltd (ROIV)

Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,460,788
  • Shares Outstanding, K 695,492
  • Annual Sales, $ 29,050 K
  • Annual Income, $ -171,980 K
  • EBIT $ -1,133 M
  • EBITDA $ -1,118 M
  • 60-Month Beta 1.22
  • Price/Sales 538.62
  • Price/Cash Flow N/A
  • Price/Book 3.23

Options Overview Details

View History
  • Implied Volatility 46.47% (+6.13%)
  • Historical Volatility 35.34%
  • IV Percentile 78%
  • IV Rank 35.37%
  • IV High 82.20% on 04/04/25
  • IV Low 26.92% on 04/14/25
  • Expected Move (DTE 20) 1.48 (6.65%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 2,593
  • Volume Avg (30-Day) 1,466
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 114,124
  • Open Int (30-Day) 117,177
  • Expected Range 20.75 to 23.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.35
  • Low Estimate -0.42
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -90.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.96 +11.37%
on 12/02/25
23.47 -5.28%
on 12/17/25
+1.36 (+6.52%)
since 11/26/25
3-Month
14.86 +49.60%
on 09/29/25
23.47 -5.28%
on 12/17/25
+7.06 (+46.54%)
since 09/26/25
52-Week
8.73 +154.64%
on 04/07/25
23.47 -5.28%
on 12/17/25
+10.23 (+85.25%)
since 12/26/24

Most Recent Stories

More News
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day

Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three years Highlighting clinical execution,...

ROIVW : 2.75 (-3.85%)
ROIV : 22.23 (-1.20%)
Novel Immunotherapy Breakthroughs Advance Blood Cancer Treatment

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing...

ZLAB : 18.33 (-1.35%)
GTBP : 0.8324 (-1.49%)
ROIV : 22.23 (-1.20%)
CCCC : 2.12 (+1.92%)
BMY : 54.64 (-0.13%)
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided...

ROIVW : 2.75 (-3.85%)
ROIV : 22.23 (-1.20%)
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business...

IMVT : 26.16 (-2.68%)
ROIV : 22.23 (-1.20%)
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November...

ROIVW : 2.75 (-3.85%)
ROIV : 22.23 (-1.20%)
This Red-Hot Biopharma Stock Could Fizzle Out Soon

Roivant Sciences (ROIV) shows strong technical momentum and is trading at new all-time highs. Shares are up 52% over the past year and 20% in the last month. ROIV has a 100% “Buy” opinion from Barchart...

ROIV : 22.23 (-1.20%)
J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

In a report released today, Brian Cheng from J.P. Morgan reiterated a Buy rating on Roivant Sciences, with a price target of $20.00. The company’s shares closed yesterday at $16.12.Elevate Your Investing...

ROIV : 22.23 (-1.20%)
Stocks Settle Mixed on Hawkish Fed Chair Powell Comments

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.57%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.21%. September...

PYPL : 59.97 (-0.12%)
NVDA : 190.53 (+1.02%)
WY : 23.74 (-0.08%)
$SPX : 6,929.94 (-0.03%)
BLDR : 103.99 (-0.04%)
ROIV : 22.23 (-1.20%)
$IUXX : 25,644.39 (-0.05%)
NQH26 : 25,863.25s (-0.07%)
WDAY : 220.70 (+1.78%)
ZG : 69.59 (+1.07%)
QQQ : 623.89 (-0.01%)
ZNH26 : 112-185s (+0.06%)
The Federal Reserve Cuts Interest Rate by a Quarter-Percentage-Point, Signals 2 More Before the End of the Year

The S&P 500 Index ($SPX ) (SPY ) today is up -0.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.77%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.80%. In a move that was largely...

NVDA : 190.53 (+1.02%)
META : 663.29 (-0.64%)
GOOGL : 313.51 (-0.18%)
$SPX : 6,929.94 (-0.03%)
ROIV : 22.23 (-1.20%)
$IUXX : 25,644.39 (-0.05%)
WDAY : 220.70 (+1.78%)
ZG : 69.59 (+1.07%)
DUOL : 181.66 (+0.54%)
QQQ : 623.89 (-0.01%)
ZNH26 : 112-185s (+0.06%)
MSFT : 487.71 (-0.06%)
Stocks Narrowly Mixed Ahead of FOMC Decision

The S&P 500 Index ($SPX ) (SPY ) today is up +0.04%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.12%. September E-mini S&P futures...

NVDA : 190.53 (+1.02%)
AVGO : 352.13 (+0.55%)
$SPX : 6,929.94 (-0.03%)
ROIV : 22.23 (-1.20%)
$IUXX : 25,644.39 (-0.05%)
NQH26 : 25,863.25s (-0.07%)
WDAY : 220.70 (+1.78%)
ZG : 69.59 (+1.07%)
DUOL : 181.66 (+0.54%)
ASML : 1,072.75 (+0.68%)
QQQ : 623.89 (-0.01%)
ZNH26 : 112-185s (+0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 22.73
2nd Resistance Point 22.57
1st Resistance Point 22.40
Last Price 22.23
1st Support Level 22.07
2nd Support Level 21.91
3rd Support Level 21.74

See More

52-Week High 23.47
Last Price 22.23
Fibonacci 61.8% 17.84
Fibonacci 50% 16.10
Fibonacci 38.2% 14.36
52-Week Low 8.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar